The trial, sponsored by Johns Hopkins University, aimed to evaluate the safety and tolerability of the ketogenic diet in ALS patients with gastrostomy tubes. Although the study has been terminated, it highlights the growing interest in dietary interventions for neurodegenerative diseases, particularly ALS. The market for ALS treatments is competitive, with existing therapies like Riluzole and emerging gene therapies. Companies exploring dietary supplements or nutritional interventions may find strategic opportunities, especially if safety data supports further investigation. Diligence should focus on the regulatory landscape surrounding dietary supplements and the potential for partnerships with academic institutions.